Skip to main content
. 2014 May 13;5(11):3622–3635. doi: 10.18632/oncotarget.1969

Figure 6. In vitro and vivo antitumor efficacy of DHA-GEM on H22 cells and H22 tumor-bearing mice.

Figure 6

A, Cell viability of H22 cells incubated with DHA-GEM and free gemcitabine. B, tumor volume of mice-bearing H22 tumors under different treatments (saline, free gemcitabine, or DHA-GEM, n=10/group). C, tumor weight and tumor picture of mice-bearing H22 tumors in different groups(saline, free gemcitabine, or DHA-GEM) on the 9th day after injection. D, body weights of mice bearing H22 tumors in different groups. E, the 20-day survival rates of mice after administration of saline, free gemcitabine, or DHA-GEM. F, hematoxylin and eosin-stained hearts, tumors, livers and kidneys of saline treated mice, gemcitabine-treated mice,or DHA-GEM–treated mice. Data are given as mean ± SD (n=10). **, P<0.01.